http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-2022005072-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c1ee19e6efdf91c1bf88bde9e9845ef
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
filingDate 2022-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc17392ca7cb3999c32ec3af595cd211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec7b6e8a7ef27a83009291a078d413cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d75a42ca7c7ba388279565911ec7bf48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58eea9cb72a6c8da6962fc1f35fe22a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed816a4281229d7f70b856d1370b408e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856fc87ceeaa1f64df12867f57dcf964
publicationDate 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CO-2022005072-A2
titleOfInvention Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives that have multimodal activity against pain
abstract The present invention relates to homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having dual pharmacological activity towards both the α2δ subunit of the voltage-gated calcium channel and the sigma-1 (σ1) receptor, to preparation processes of said compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
priorityDate 2019-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447970895
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135570465

Total number of triples: 33.